John Carpten

Title: Innovations in Cancer Treatment by John Carpten

Introduction

John Carpten is a prominent inventor based in Phoenix, AZ, known for his significant contributions to cancer research and treatment. With a total of five patents to his name, Carpten has focused on developing targeted therapies that address specific genetic events in cancer.

Latest Patents

Carpten's latest patents revolve around targeted therapies for cancer, particularly those involving the NRG1 fusion event. These patents provide compositions and methods for detecting cancers that contain this specific genetic alteration. The therapeutic agents described in his patents include inhibitors of the Epidermal Growth Factor Receptor and/or ERBB2. Notable examples of these agents are cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In some embodiments, a combination of trastuzumab and pertuzumab is proposed as a therapeutic strategy.

Career Highlights

Throughout his career, John Carpten has made significant strides in the field of cancer research. He has worked with esteemed organizations such as the Translational Genomics Research Institute and the Mayo Foundation for Medical Education and Research. His work has been instrumental in advancing the understanding of cancer genetics and developing innovative treatment options.

Collaborations

Carpten has collaborated with notable colleagues in the field, including David Craig and Mitesh J Borad. These collaborations have further enriched his research and contributed to the development of effective cancer therapies.

Conclusion

John Carpten's innovative work in targeted cancer therapies highlights his commitment to improving patient outcomes through scientific research. His contributions continue to shape the landscape of cancer treatment and offer hope for patients facing challenging diagnoses.